178 related articles for article (PubMed ID: 19465159)
1. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.
Peyrin-Biroulet L; Colombel JF; Sandborn WJ
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1139. PubMed ID: 19465159
[No Abstract] [Full Text] [Related]
2. [Biological compounds in the treatment of Crohn's disease].
Dinari G
Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
[No Abstract] [Full Text] [Related]
3. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis.
Epstein D; Watermeyer G; Kirsch R
Aliment Pharmacol Ther; 2007 Jun; 25(12):1373-88. PubMed ID: 17539977
[TBL] [Abstract][Full Text] [Related]
4. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease.
Bruining DH; Sandborn WJ
Clin Gastroenterol Hepatol; 2011 May; 9(5):395-9. PubMed ID: 21277392
[TBL] [Abstract][Full Text] [Related]
5. Review article: loss of response to anti-TNF treatments in Crohn's disease.
Ben-Horin S; Chowers Y
Aliment Pharmacol Ther; 2011 May; 33(9):987-95. PubMed ID: 21366636
[TBL] [Abstract][Full Text] [Related]
6. Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
Prescrire Int; 2008 Aug; 17(96):145. PubMed ID: 19489184
[TBL] [Abstract][Full Text] [Related]
7. [Tumor necrosis factor a inhibitors in treatment of Crohn's disease].
Vermel' AE
Klin Med (Mosk); 2005; 83(11):13-7. PubMed ID: 16404932
[No Abstract] [Full Text] [Related]
8. Anti-tumor necrosis factor therapy in Crohn's disease: more information and more questions about the long term.
Bernstein CN
Clin Gastroenterol Hepatol; 2010 Jul; 8(7):556-8. PubMed ID: 20417722
[No Abstract] [Full Text] [Related]
9. Biologics in pediatric Crohn's disease: is it time to move to an earlier therapeutic approach?
Hyams JS
Expert Rev Clin Immunol; 2014 Nov; 10(11):1423-6. PubMed ID: 25340425
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy in Crohn's disease.
Williams MD; Omran ML; Gordon GL
Mo Med; 2009; 106(5):356-60. PubMed ID: 19902717
[TBL] [Abstract][Full Text] [Related]
11. [From research to clinic: The case of Crohn's disease and Tumor Necrosis Factor].
Pellicano R
Minerva Gastroenterol Dietol; 2000 Jun; 46(2):131-8. PubMed ID: 19320082
[No Abstract] [Full Text] [Related]
12. [Is Crohn's disease an indication for growth hormone treatment?].
Szalecki M; Ziora K
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):237-40. PubMed ID: 17020663
[TBL] [Abstract][Full Text] [Related]
13. Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.
Roberts RL; Barclay ML
J Gastroenterol Hepatol; 2012 Oct; 27(10):1546-54. PubMed ID: 22741564
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Crohn's disease.
Rutgeerts PJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S1-2. PubMed ID: 15580147
[No Abstract] [Full Text] [Related]
15. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
[No Abstract] [Full Text] [Related]
16. Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?
Dubinsky MC
Rev Gastroenterol Disord; 2007; 7 Suppl 2():S3-7. PubMed ID: 17392637
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.
Picco MF; Zubiaurre I; Adluni M; Cangemi JR; Shelton D
Am J Gastroenterol; 2009 Nov; 104(11):2754-9. PubMed ID: 19584832
[TBL] [Abstract][Full Text] [Related]
18. Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?
Rogler G
Aliment Pharmacol Ther; 2016 Mar; 43(5):651-2. PubMed ID: 26843342
[No Abstract] [Full Text] [Related]
19. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
Siegel CA; Marden SM; Persing SM; Larson RJ; Sands BE
Clin Gastroenterol Hepatol; 2009 Aug; 7(8):874-81. PubMed ID: 19558997
[TBL] [Abstract][Full Text] [Related]
20. Griseofulvin: a potential addition to anti-Crohn's disease armamentarium.
Namazi MR
Scand J Gastroenterol; 2005 Feb; 40(2):244-5. PubMed ID: 15764160
[No Abstract] [Full Text] [Related]
[Next] [New Search]
